C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

C4 Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.3 million for Q2 2023.

• On a quarterly basis, Non-Current Debt changed 0.36% year-over-year to $10.3 million in Q2 2023; TTM through Jun 2023 was $10.3 million, a 0.36% change from a year earlier, with the FY2022 full-year figure at $9.2 million, down 14.61% from the prior year.
• Non-Current Debt fell to $10.3 million in Q2 2023 per CCCC's latest filing, from $11.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $11.8 million in Q1 2023 and bottomed at $9.1 million in Q3 2022.
• The 4-year median for Non-Current Debt is $10.3 million (2021), against an average of $10.2 million.
• Across the five-year window, Non-Current Debt slipped 14.61% in 2022 and gained 15.26% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $10.1 million in 2020, then grew by 7.12% to $10.8 million in 2021, then fell by 14.61% to $9.2 million in 2022, then rose by 12.4% to $10.3 million in 2023.
• Per Business Quant, the three latest CCCC Non-Current Debt figures stand at $10.3 million (Q2 2023), $11.8 million (Q1 2023), and $9.2 million (Q4 2022).